» Articles » PMID: 28674415

MBOAT7 Rs641738 Variant and Hepatocellular Carcinoma in Non-cirrhotic Individuals

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents an emerging cause of hepatocellular carcinoma (HCC), especially in non-cirrhotic individuals. The rs641738 C > T MBOAT7/TMC4 variant predisposes to progressive NAFLD, but the impact on hepatic carcinogenesis is unknown. In Italian NAFLD patients, the rs641738 T allele was associated with NAFLD-HCC (OR 1.65, 1.08-2.55; n = 765), particularly in those without advanced fibrosis (p < 0.001). The risk T allele was linked to 3'-UTR variation in MBOAT7 and to reduced MBOAT7 expression in patients without severe fibrosis. The number of PNPLA3, TM6SF2, and MBOAT7 risk variants was associated with NAFLD-HCC independently of clinical factors (p < 0.001), but did not significantly improve their predictive accuracy. When combining data from an independent UK NAFLD cohort, in the overall cohort of non-cirrhotic patients (n = 913, 41 with HCC) the T allele remained associated with HCC (OR 2.10, 1.33-3.31). Finally, in a combined cohort of non-cirrhotic patients with chronic hepatitis C or alcoholic liver disease (n = 1121), the T allele was independently associated with HCC risk (OR 1.93, 1.07-3.58). In conclusion, the MBOAT7 rs641738 T allele is associated with reduced MBOAT7 expression and may predispose to HCC in patients without cirrhosis, suggesting it should be evaluated in future prospective studies aimed at stratifying NAFLD-HCC risk.

Citing Articles

Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.

Bourganou M, Chondrogianni M, Kyrou I, Flessa C, Chatzigeorgiou A, Oikonomou E Int J Mol Sci. 2025; 26(4).

PMID: 40004054 PMC: 11855544. DOI: 10.3390/ijms26041589.


Risk-stratified hepatocellular carcinoma surveillance in non-cirrhotic patients with MASLD.

Mi K, Ye T, Zhu L, Pan C Gastroenterol Rep (Oxf). 2025; 13:goaf018.

PMID: 39980834 PMC: 11842057. DOI: 10.1093/gastro/goaf018.


Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application.

Chen V, Brady G Hepatol Commun. 2025; 9(1.

PMID: 39774697 PMC: 11717516. DOI: 10.1097/HC9.0000000000000618.


Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease.

Pei Y, Goh G Gut Liver. 2025; 19(1):8-18.

PMID: 39774124 PMC: 11736312. DOI: 10.5009/gnl240407.


Deep metabolic phenotyping of humans with protein-altering variants in using a genome-first approach.

Huang H, Vitali C, Zhang D, Hand N, Phillips M, Creasy K JHEP Rep. 2024; 7(1):101243.

PMID: 39687601 PMC: 11647476. DOI: 10.1016/j.jhepr.2024.101243.


References
1.
Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V . Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2008; 49(3):851-9. DOI: 10.1002/hep.22734. View

2.
Sookoian S, Pirola C . Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011; 53(6):1883-94. DOI: 10.1002/hep.24283. View

3.
Smagris E, BasuRay S, Li J, Huang Y, Lai K, Gromada J . Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology. 2014; 61(1):108-18. PMC: 4262735. DOI: 10.1002/hep.27242. View

4.
Baffy G, Brunt E, Caldwell S . Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012; 56(6):1384-91. DOI: 10.1016/j.jhep.2011.10.027. View

5.
Dongiovanni P, Petta S, Mannisto V, Mancina R, Pipitone R, Karja V . Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015; 63(3):705-12. DOI: 10.1016/j.jhep.2015.05.006. View